GTx is developing Capesaris® (GTx-758), a selective estrogen receptor (ER) alpha agonist, for primary
androgen deprivation therapy (first-line) and secondary hormonal treatment of men with advanced prostate cancer.
Capesaris rapidly suppresses secretion of luteinizing hormone by feedback inhibition on the pituitary,
thereby inhibiting the production of androgens by the testes. Capesaris® has the potential to achieve medical castration
to control the prostate cancer and to prevent bone loss and hot flashes. Capesaris® also induces the liver to secrete sex
hormone binding globulin, a protein which binds to and markedly reduces levels of serum free testosterone, which is
the form of testosterone that is available to bind to androgen receptors in the prostate.